Abstract
Mutant KRAS promotes type 2 immunity through upregulation of IL33 in pancreatic ductal adenocarcinoma (PDAC).
©2022 American Association for Cancer Research.
2022
American Association for Cancer Research.
You do not currently have access to this content.